MedRhythms’ Feasibility Study Shows Positive Topline Results in Parkinson’s Disease

February 3, 2023

(From PR Newswire) MedRhythms recently announced the successful completion of a multi-site feasibility study of MR-005, its investigational asset in development for the treatment of gait deficits in Parkinson's disease (PD). The study results revealed enhanced quality of life and high patient adherence rates. Additionally, preliminary results showed improvement in motor symptoms of PD. MTI played a significant role in the growth and development of the Portland-based company.

Read more here.